Plain-English translation of NCT06952452 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing whether genetic differences in your body affect how well two different medications work for treating wet age-related macular degeneration (wAMD)—a condition where abnormal blood vessels grow under the retina and damage vision. Researchers will compare ranibizumab and , two medications that are injected directly into the eye to stop this abnormal blood vessel growth. The study will track your vision and eye health for 3 years to see which medication works better for you personally.
Wet age-related macular degeneration can cause serious vision loss, and doctors need to know whether genetic factors help predict which medication will work best for each patient. This could help doctors choose the right treatment faster and improve outcomes for people with this condition.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of the two medications and will get three injections into your eye spaced 4–6 weeks apart. Over 3 years, you will have regular eye exams and imaging tests to measure how well the treatment is working and to check for any side effects. You will also provide a saliva sample so researchers can analyze your genes to understand how they may influence your response to the medication.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Spain